Correlative factors of left ventricular hypertrophy in end-stage renal disease

Abstract

The correlative factors of left ventricular hypertrophy (LVH) in 287 endstage renal disease (ESRD), admitted from 1983 to 1992, were analyzed. 52% of patients had LVH including 54 % of patients on hemodialysis, 75 % of patients with peritoneal dialysis and 38 % of transplanted patients. Single factor analysis indicated that age, blood pressure, serum creatinine and BUN, hemoglobin, serum alkaline phosphatase, aortic valve disease and present DSRD therapy were related to LVH. Multiple logistic regression analysis indicated that the most important factors which independently related to LVH in all patients studied, were management of present ESRD treatment, age, hypertension and high serum alkaline phosphatase. In a subset of patients with severe LVH, high serum alkaline phosphatase level, high systolic blood pressure and age were the predictive factors. In patients on dialysis, the most important variable were age and high serum alkaline phosphatase. Hypertension was the sole predictor of LVH in the transplant group.

Keywords

end-stage renal disease / left ventricular hypertrophy / dialysis / transplantation

References

[1] MaK W, GreeneE L, RaijL. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kidney Dis, 1992, 19(6): 505-505

[2] RostandS G, BrunzelJ D, CannonR O, et al.. Cardiovascular complications in renal failure. J Am Soc Nephrol, 1991, 2(6): 1053-1053

[3] DeligiannisA, PaschalidouE, SakellariouG, et al.. Changes in left ventricular anatomy during hemodialysis, continuous ambulatory peritoneal dialysis and after renal transplantation. Proc Eur Dial Transplant Ass, 1985, 21: 185-185

[4] SalinasC A, UlloaF, HermosilloJ A, et al.. Change in the mass and function of the left ventricle after renal transplantation. Arch Inst Cardiol Mex, 1991, 61: 527-527

[5] NailR B, GoslingP, PriceC, et al.. Comparative study of alkaline phosphatase isoenzymes, bone histology, and skeletal radiography in dialysis bone disease. Br Med J, 1977, I: 1307-1307

[6] McGoingleR J, FowlerM B, TimmisA B, et al.. Uremic cardiomyopathy: potential role of vitamine D and parathyroid hormone. Nephron, 1984, 36: 94-94

[7] de WardenerH E, MacGregorG A. The relation of a circulating sodium transport inhibitor to hypertension. Medicine, 1983, 62: 310-310

[8] FraserC L, SarnachiP, AtieffA I, et al.. Effects of parathyroid hormone in uremia on calcium transport in rat brain synaptosmoes. Kidney Int, 1986, 29: 159-159

[9] IsekiK, MassryS G, CampeseWM. Hypercalcemia and hypertension: role of parathyroid hormone. Kidney Int, 1986, 29: 248-248

[10] RambausckM, RitzE, MahisO, et al.. Myocardial hypertrophy in rats with renal insufficiency. Kidney Int, 1985, 28: 775-775

[11] RenJ F, HakkiA H, KotlerM N, et al.. Exercise systolic blood pressure: a powerful determinant of increased left ventricular mass in patients with hypertension. J Am Coll Cardiiol, 1985, 5: 1224-1224

[12] GardinJ M, MatinK, WhiteD, et al.. Effect of aging on peak systolic well stress in normal subjects. Clin Res, 1985, 33: 7-7